AU2002302549A1 - A method for differentiating stem cells into insulin-producing cells - Google Patents
A method for differentiating stem cells into insulin-producing cellsInfo
- Publication number
- AU2002302549A1 AU2002302549A1 AU2002302549A AU2002302549A AU2002302549A1 AU 2002302549 A1 AU2002302549 A1 AU 2002302549A1 AU 2002302549 A AU2002302549 A AU 2002302549A AU 2002302549 A AU2002302549 A AU 2002302549A AU 2002302549 A1 AU2002302549 A1 AU 2002302549A1
- Authority
- AU
- Australia
- Prior art keywords
- cells
- insulin
- differentiation
- producing cells
- stem cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000004027 cell Anatomy 0.000 title claims description 262
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims description 215
- 229940125396 insulin Drugs 0.000 title claims description 110
- 102000004877 Insulin Human genes 0.000 title claims description 106
- 108090001061 Insulin Proteins 0.000 title claims description 106
- 238000000034 method Methods 0.000 title claims description 59
- 210000000130 stem cell Anatomy 0.000 title claims description 38
- 230000004069 differentiation Effects 0.000 claims description 81
- 108090000623 proteins and genes Proteins 0.000 claims description 64
- 101150075928 Pax4 gene Proteins 0.000 claims description 45
- 239000002609 medium Substances 0.000 claims description 42
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 38
- 239000008103 glucose Substances 0.000 claims description 38
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims description 36
- 206010012601 diabetes mellitus Diseases 0.000 claims description 35
- 101710183548 Pyridoxal 5'-phosphate synthase subunit PdxS Proteins 0.000 claims description 31
- 210000002242 embryoid body Anatomy 0.000 claims description 26
- 229960004666 glucagon Drugs 0.000 claims description 19
- 150000001875 compounds Chemical class 0.000 claims description 18
- 102000051325 Glucagon Human genes 0.000 claims description 17
- 108060003199 Glucagon Proteins 0.000 claims description 17
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 14
- 239000012894 fetal calf serum Substances 0.000 claims description 14
- 101150081664 PAX6 gene Proteins 0.000 claims description 13
- 230000003914 insulin secretion Effects 0.000 claims description 12
- 238000002054 transplantation Methods 0.000 claims description 12
- 102000007354 PAX6 Transcription Factor Human genes 0.000 claims description 11
- 101000603702 Homo sapiens Neurogenin-3 Proteins 0.000 claims description 10
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 10
- 239000003797 essential amino acid Substances 0.000 claims description 10
- 235000020776 essential amino acid Nutrition 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 9
- 102000008730 Nestin Human genes 0.000 claims description 9
- 108010088225 Nestin Proteins 0.000 claims description 9
- 102100038553 Neurogenin-3 Human genes 0.000 claims description 9
- 210000005055 nestin Anatomy 0.000 claims description 9
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 claims description 8
- 239000002299 complementary DNA Substances 0.000 claims description 8
- 229930182816 L-glutamine Natural products 0.000 claims description 7
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 7
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 6
- -1 Nkx6.2 Proteins 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 239000003102 growth factor Substances 0.000 claims description 6
- 201000001421 hyperglycemia Diseases 0.000 claims description 6
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 6
- 230000001105 regulatory effect Effects 0.000 claims description 6
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 5
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 5
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 5
- 230000003213 activating effect Effects 0.000 claims description 5
- 230000004913 activation Effects 0.000 claims description 5
- 230000037396 body weight Effects 0.000 claims description 5
- 239000000186 progesterone Substances 0.000 claims description 5
- 229960003387 progesterone Drugs 0.000 claims description 5
- 108020004414 DNA Proteins 0.000 claims description 4
- 102100022057 Hepatocyte nuclear factor 1-alpha Human genes 0.000 claims description 4
- 101001045751 Homo sapiens Hepatocyte nuclear factor 1-alpha Proteins 0.000 claims description 4
- 208000016222 Pancreatic disease Diseases 0.000 claims description 4
- 108700008625 Reporter Genes Proteins 0.000 claims description 4
- 238000012835 hanging drop method Methods 0.000 claims description 4
- 208000024691 pancreas disease Diseases 0.000 claims description 4
- 102000016970 Follistatin Human genes 0.000 claims description 3
- 108010014612 Follistatin Proteins 0.000 claims description 3
- 108700014808 Homeobox Protein Nkx-2.2 Proteins 0.000 claims description 3
- 102100028098 Homeobox protein Nkx-6.1 Human genes 0.000 claims description 3
- 101000578254 Homo sapiens Homeobox protein Nkx-6.1 Proteins 0.000 claims description 3
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 3
- 102100032063 Neurogenic differentiation factor 1 Human genes 0.000 claims description 3
- 108050000588 Neurogenic differentiation factor 1 Proteins 0.000 claims description 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 3
- 210000004504 adult stem cell Anatomy 0.000 claims description 3
- 230000004931 aggregating effect Effects 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 210000004602 germ cell Anatomy 0.000 claims description 3
- 230000001771 impaired effect Effects 0.000 claims description 3
- 208000030159 metabolic disease Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 230000000638 stimulation Effects 0.000 claims description 3
- 238000012546 transfer Methods 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- 108010059616 Activins Proteins 0.000 claims description 2
- 102000005606 Activins Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- 102000008186 Collagen Human genes 0.000 claims description 2
- 102000018997 Growth Hormone Human genes 0.000 claims description 2
- 108010051696 Growth Hormone Proteins 0.000 claims description 2
- 239000000488 activin Substances 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- 230000001747 exhibiting effect Effects 0.000 claims description 2
- 239000000122 growth hormone Substances 0.000 claims description 2
- 230000000977 initiatory effect Effects 0.000 claims description 2
- 210000001988 somatic stem cell Anatomy 0.000 claims description 2
- 238000013518 transcription Methods 0.000 claims description 2
- 230000035897 transcription Effects 0.000 claims description 2
- 238000001476 gene delivery Methods 0.000 claims 2
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims 1
- 101100126336 Mus musculus Ism1 gene Proteins 0.000 claims 1
- 230000024245 cell differentiation Effects 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
- 241001465754 Metazoa Species 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 230000014509 gene expression Effects 0.000 description 15
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 239000001963 growth medium Substances 0.000 description 12
- 238000007747 plating Methods 0.000 description 12
- 229940088597 hormone Drugs 0.000 description 11
- 239000005556 hormone Substances 0.000 description 11
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 210000000496 pancreas Anatomy 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 8
- 241000701022 Cytomegalovirus Species 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 229960000553 somatostatin Drugs 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 6
- 238000000137 annealing Methods 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 6
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 5
- 108010056088 Somatostatin Proteins 0.000 description 5
- 102000005157 Somatostatin Human genes 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000011712 cell development Effects 0.000 description 5
- 238000004520 electroporation Methods 0.000 description 5
- 230000013020 embryo development Effects 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 210000004153 islets of langerhan Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 5
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 4
- 102100024392 Insulin gene enhancer protein ISL-1 Human genes 0.000 description 4
- 108010085895 Laminin Proteins 0.000 description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- 229930193140 Neomycin Natural products 0.000 description 4
- 101100519293 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pdx-1 gene Proteins 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 101150111723 PDX1 gene Proteins 0.000 description 4
- 102000004338 Transferrin Human genes 0.000 description 4
- 108090000901 Transferrin Proteins 0.000 description 4
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 4
- 230000002124 endocrine Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000010363 gene targeting Methods 0.000 description 4
- 238000013537 high throughput screening Methods 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 229960004927 neomycin Drugs 0.000 description 4
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 229960001471 sodium selenite Drugs 0.000 description 4
- 239000011781 sodium selenite Substances 0.000 description 4
- 235000015921 sodium selenite Nutrition 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 239000012581 transferrin Substances 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 108700039887 Essential Genes Proteins 0.000 description 3
- 108010067306 Fibronectins Proteins 0.000 description 3
- 102000016359 Fibronectins Human genes 0.000 description 3
- 102000008070 Interferon-gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 101150070110 Isl1 gene Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000018886 Pancreatic Polypeptide Human genes 0.000 description 3
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000004243 Tubulin Human genes 0.000 description 3
- 108090000704 Tubulin Proteins 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000000721 bacterilogical effect Effects 0.000 description 3
- 208000036815 beta tubulin Diseases 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 210000003890 endocrine cell Anatomy 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 3
- 229960005542 ethidium bromide Drugs 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 210000002660 insulin-secreting cell Anatomy 0.000 description 3
- 229960003130 interferon gamma Drugs 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 239000013615 primer Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 229960001052 streptozocin Drugs 0.000 description 3
- 238000004114 suspension culture Methods 0.000 description 3
- 238000010200 validation analysis Methods 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 2
- 102000058058 Glucose Transporter Type 2 Human genes 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 2
- 241001135569 Human adenovirus 5 Species 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 102100041030 Pancreas/duodenum homeobox protein 1 Human genes 0.000 description 2
- 108700020479 Pancreatic hormone Proteins 0.000 description 2
- 239000005700 Putrescine Substances 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 108091006299 SLC2A2 Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 108010023082 activin A Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000007877 drug screening Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000008472 epithelial growth Effects 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 208000004104 gestational diabetes Diseases 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 230000015031 pancreas development Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 229950010131 puromycin Drugs 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000010187 selection method Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- HWQQCFPHXPNXHC-UHFFFAOYSA-N 6-[(4,6-dichloro-1,3,5-triazin-2-yl)amino]-3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=CC=2)OC(=O)C1=CC=2NC1=NC(Cl)=NC(Cl)=N1 HWQQCFPHXPNXHC-UHFFFAOYSA-N 0.000 description 1
- HFDKKNHCYWNNNQ-YOGANYHLSA-N 75976-10-2 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 HFDKKNHCYWNNNQ-YOGANYHLSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000012583 B-27 Supplement Substances 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010027344 Basic Helix-Loop-Helix Transcription Factors Proteins 0.000 description 1
- 102000018720 Basic Helix-Loop-Helix Transcription Factors Human genes 0.000 description 1
- 102400001242 Betacellulin Human genes 0.000 description 1
- 101800001382 Betacellulin Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101150066002 GFP gene Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000921786 Homo sapiens Cystatin-A Proteins 0.000 description 1
- 101001053263 Homo sapiens Insulin gene enhancer protein ISL-1 Proteins 0.000 description 1
- 101000612089 Homo sapiens Pancreas/duodenum homeobox protein 1 Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 101710096141 Neurogenin-3 Proteins 0.000 description 1
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 1
- 241000881705 Porcine endogenous retrovirus Species 0.000 description 1
- 101710149951 Protein Tat Proteins 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101150116689 Slc2a2 gene Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 230000021617 central nervous system development Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 238000012203 high throughput assay Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000005155 neural progenitor cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 210000000277 pancreatic duct Anatomy 0.000 description 1
- 230000009996 pancreatic endocrine effect Effects 0.000 description 1
- 210000003577 pancreatic endocrine progenitor Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 101150079312 pgk1 gene Proteins 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011536 re-plating Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 210000002325 somatostatin-secreting cell Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- YFDSDPIBEUFTMI-UHFFFAOYSA-N tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 1
- 229950004616 tribromoethanol Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011311 validation assay Methods 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Description
A Method For Differentiating Stem Cells into Insulin-Producing Cells
Description
FIELD OF THE INVENTION
The present invention relates to methods for differentiating stem cells into insulin-producing cells by culturing such cells in specially defined mediums and optimally, activating one or more genes involved in beta-cell differentiation. The present invention provides means for treatment of pancreatic diseases, metabolic syndrome and metabolic disorders with impaired glucose levels, for instance, but not limited to, diabetes mellitus, hyperglycaemia and impaired glucose tolerance, by transplanting said insulin-producing cells into diabetic animals and humans. The methods can further be used to generate cells for the identification and characterisation of compounds which stimulate beta-cell differentiation, insulin secretion or glucose responsiveness. Differentiated insulin-producing cells can also be used to study the toxic and other effects of exogenous compounds on beta-cell function.
BACKGROUND OF THE INVENTION
Diabetes, hyperglycaemia and impaired glucose tolerance are endocrine disorders characterised by inadequate production or use of insulin, which affects the metabolism of carbohydrates, proteins, and lipids resulting in abnormal levels of glucose in the blood. Diabetes is a heterogeneous disease that can be classified into two major group: Type 1 diabetes (also known as Insulin-dependent diabetes, IDDM, type I, juvenile diabetes) and Type 2 diabetes (Noninsulin-dependent diabetes, NIDDM, type II, maturity- onset diabetes) .
The functional unit of the endocrine pancreas is the islet of Langerhans which are scattered throughout the exocrine portion of the pancreas and are composed of four cell types: alpha-, beta-, delta-, and PP-cells. Beta- cells produce insulin, represent the majority of the endocrine cells and form the core of the islets while alpha-cells secrete glucagon and are located in the periphery. Delta-cells and PP-cells are less numerous and secrete somatostatin and a pancreatic polypeptide respectively. Insulin and glucagon are key regulators of blood glucose levels. Insulin lowers blood glucose levels by increasing its cellular uptake and conversion into glycogen. Glucagon elevates blood glucose levels by intervening in the breakdown of liver glycogen. Type 1 diabetes is characterised by an autoimmune destruction of insulin-producing beta-cells. Type 2 diabetes is characterised by insulin resistance and impaired glucose tolerance where insulin is not efficiently used or is produced in insufficient amounts by the beta-cells. Therefore, type 2 patients often require additional insulin to regulate blood glucose levels. Consequently, there is little therapeutic difference in the administration of insulin between type 1 and type 2 diabetic patients ( see Fajans in Diabetes Milletus fifth editions; Porte and Sherwin, ed; Appleton & Lange pub. 1 997, 1423pp) . Individuals afflicted with diabetes must inject themselves up to six times a day with insulin.
Despite insulin injections, diabetic patients develop complications and their susceptibility to strokes, blindness, amputations, kidney and cardiovascular diseases is greatly increased while their life expectancy is shortened (Nathan (1 993) N. Engl. J. Med. 328: 1 676-1 685; Group, T. D. C. a. C. T. R. (1 993) N. Engl. J. Med. 329:977-986) . Replacement of absent insulin- producing cells by transplantation of islets of Langerhans or insulin- producing cells is one promising therapeutic option (Luzi et al. (1 996) J. Clin. Invest. 97:261 1 -261 8; Bretzel et al. (1 996) Ther. Umsch. 53:889- 901 ) However, the availability of human donor tissue for transplantation is severely limited. An alternative option would be the use of animal tissues from pigs but serious technical problems such as long term
immunosuppression and the risk of transferring a porcine pathogen such as porcine endogenous retrovirus into the human population must be solved (Butler et al. (1 998) Nature 391 :320-324; Bach et al. (1 998) Nature Med. 4: 141 -144; Shapiro et al. (2000) N. Engl. J. Med. 343:230-238). One solution to this problem would be to generate a human "surrogate cell" capable of assuming the functions of the missing or malfunctioning beta- cell. Therefore, there exists a need for producing an unlimited amount of surrogate insulin-producing cells for transplantation into diabetic patients. The present invention satisfies this need by providing an easy method for inducing the differentiation of stem cells into functional insulin-producing cells.
Stem cells are undifferentiated or immature cells that can give rise to various specialised cell types. Once differentiated or induced to differentiate, stem cells can be used to repair damaged and malfunctioning organs. Stem cells can be of embryonic or adult origin. Adult or somatic stem cells have been identified in numerous different tissues such as muscle, bone marrow, liver, and brain (Vescovi and Snyder (1 999) Brain Pathol., 9:569-598; Seale and Rudnicki (2000) Dev. Biol., 218: 1 1 5-1 24) . In the pancreas, several indications suggest that stem cells are also present within the adult tissue (Gu and Sarvetnick (1 993) Development, 1 18:33- 46; Bouwens (1 998) Microsc Res Tech, 43:332-336; Bonner-Weir (2000) J. Mol. Endocr., 24:297-302). However, this population is poorly defined and represents a very small percentage of cells in the pancreas.
Embryonic stem cells can be isolated from the inner cell mass of pre- implantation embryos (ES cells) or from the primordial germ cells found in the genital ridges of post-implanted embryos (EG cells) . When grown in special culture conditions such as spinner culture or hanging drops, both ES and EG cells aggregate to form embrγoid bodies (EB) . EBs are composed of various cell types similar to those present during embryogenesis. When cultured in appropriate media, EB can be used to
generate in vitro differentiated phenotypes, such as extraembryonic endoderm, hematopoietic cells, neurons, cardiomyocytes, skeletal muscle cells, and vascular cells. No method has been described so far that allows EB to efficiently differentiate into insulin-producing cells.
Soria and colleagues describe a method for selecting insulin-secreting cell clones from ES cells using a cell-trapping system, wherein cells are transfected with a plasmid allowing the expression of neomycin resistance gene under the control of the regulatory region of the human insulin gene. Cells from an insulin-secreting cell clone were implanted in the spleen of diabetic mice. The implanted cells can normalise blood glucose levels and restore body weight in the treated animals (Soria et al. (2000) Diabetes 49: 1 57-1 62) . A disadvantage of this selection method is, however, its low efficiency.
Lumelsky and colleagues (Lumelsky et al. (May 2001 ), Science 292: 1 389- 1 394) have generated insulin-expressing cells from mouse ES cells. ES cells are expanded on a gelatine-coated tissue culture surface without feeder cells and in the presence of LIF. Then, embryoid bodies are generated in suspension in ES cell medium in the absence of LIF. In a further stage nestin-positive cells are selected in a serum-free medium (ITSFn) on tissue culture surface. Resulting pancreatic endocrine progenitor cells are expanded and the differentiation and morphogenesis of insulin- secreting islet clusters is induced. However, the insulin-secreting islet clusters did not restore normal blood glucose levels when transplanted into diabetic mice.
Assady et al. (August 2001 ), Diabetes, 50: 1 -7) describe a spontaneous in vitro differentiation of pluripotent human embryonic stem cells into cells having the characteristics of insulin-producing cells. Secretion of insulin into the medium was observed in a differentiation-dependent manner and was associated with the appearance of other β-cell markers. However, the
efficiency of differentiation was low with only 1 -3% of differentiated cells positive for insulin.
The present invention is aimed at inducing the differentiation of ES cells by activation of specific genes into insulin-producing cells and is therefore different from the methods of the prior art designed to select such cells.
In recent years, several genes have been shown to be essential for the generation of pancreatic endocrine cells during embryogenesis (Edlund ( 1 998) Diabetes, 47: 1 81 7-1 823; St-Onge et al. (1 999) Curr. Opin. Genet. Dev., 9:295-300). Pancreas development involves a series of inductive signals emanating from the surrounding mesodermic tissues and transcription factors expressed in the pancreatic epithelium. The homeobox containing transcription factor Pdx1 (also referred to Idx1 , STF1 , IPF1 ) is expressed in all cells of the pancreatic buds during development and will become restricted to the beta-cells in adult animals. Pdx1 mutant mice do not develop any exocrine nor endocrine tissue and do not have any pancreas (Jonsson et al. (1 994) Nature, 371 :606-609; Ahlgren et al. (1 996) Development, 122: 1409-141 6; Offield et al. (1 996) Development, 122:983-995) The basic helix-loop-helix transcription factor neurogenin3 (ngn3) is required for the specification of the early endocrine precursor in the pancreatic epithelium and is downregulated once endocrine differentiation begins (Apelqvist ef al. (1 999) Nature, 400:877-881 ; Jensen et al. (2000) Diabetes, 49: 1 63-1 76; Gradwohl et al. (2000) Proc. Natl. Acad. Sci. U.S.A., 97: 1 607-1 61 1 ). Two members of the Pax gene family, Pax4 and Pax6, are essential for proper differentiation of endocrine cells in the pancreas (Sosa-Pineda et al. (1 997) Nature, 386:399-402; St-Onge et al. (1 997) Nature, 397:406-409; Sanders et al (1 997) Genes Dev., 1 1 : 1 662-1 673) . Both Pax genes are expressed early in development in a subset of endocrine precursor cells of the pancreatic epithelium, before differentiation of the mature hormone-producing cells. Mice lacking Pax4 fail to develop any beta-cells and are diabetic while the alpha-cell
population is absent in Pax6 mutant mice. Nkx2.2, Nkx6.1 , Nkx6.2, Isl1 , and NeuroD are also among essential transcription factors required for the proper differentiation and function of beta-cells.
Several animal models for beta-cell regeneration suggest that the mechanisms involved in beta-cell differentiation in adult organism are similar to the mechanisms involved in beta-cell differentiation during embryogenesis. Gu and Savernick have established a model system for studying pancreatic islet and beta-cell regeneration in transgenic mice bearing the interferon-gamma (IFN-gamma) gene expressed in pancreatic islets. In this model, new islet cells (i.e. beta-, alpha-, delta- and PP-cells) are formed continuously from pancreatic duct cells (Gu and Savernick (1993) Development, 1 18:33-46). They show that duct cell proliferation and the duct-associated islet formation in IFN-gamma transgenic mice is recapitulating islet formation during development and requires the expression of Pax4, Pax6 and Pdx1 genes. Although a link exists between the genes involved in islet regeneration in adult animals and beta-cell differentiation during embryogenesis, it has not been shown in the prior art that activation of such genes in stem cells can induce the differentiation into insulin-producing cells.
SUMMARY OF THE INVENTION
The present invention relates a novel method for differentiating stem cells into insulin-producing cells by culturing such cells in specially defined media and optimally, activating one or more genes involved in beta-cell differentiation. The present invention further relates to applications in the medical and diabetes field that directly arise from the method of the invention. Additionally, the present invention relates to applications for identifying and characterising compounds with therapeutic medical effects or toxicological effects that directly arise from the method of the invention.
DETAILED DESCRIPTION OF THE INVENTION
Before the present methods are described, it is understood that this invention is not limited to the particular methodology, protocols, cell lines, vectors, and reagents described as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims. Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods, devices, and materials are now described. All publications mentioned herein are incorporated herein by reference for the purpose of describing and disclosing the cell lines, vectors, and methodologies which are reported in the publications which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.
A technical problem underlying the present invention is to provide a method for generating insulin-producing cells for transplantation in patients afflicted with pancreatic diseases, such as for example but not limited to, hyperglycaemia, impaired glucose tolerance, gestational diabetes, and diabetes mellitus. The solution to said technical problem is achieved by the embodiments characterised in the claims.
Thus, the present invention relates to methods for differentiating stem cells into insulin-producing cells comprising
(a) Activating one or more pancreatic genes in a stem cell
(b) Aggregating said cells to form embryoid bodies
(c) Cultivating embryoid bodies in specific differentiation media enhancing beta-cell differentiation
(d) Identification and selection of insulin-producing cells and of pancreatic cells.
In connection with the present invention, the term "stem cells" denotes an undifferentiated or immature embryonic, adult or somatic cells that can give rise to various specialised cell types. The term stem cells can includes embryonic stem cells (ES) and primordial germ cells (EG) cells of human or animal origin. Isolation and culture of such cells is well known to those skilled in the art (Thomson et al. (1 998) Science 282: 1 145-1 147; Shamblott et al. (1 998) Proc. Natl. Acad. Sci. USA 95: 1 3726-1 3731 ; US 6,090,622; US 5,914,268; WO 0027995; Notarianni et al. (1 990) J. Reprod. Fert. 41 :51 -56; Vassilieva et al. (2000) Exp. Cell. Res. 258:361 - 373) . The term "stem cells" can include neural progenitor cells from embryonic, fetal or adult neural tissues. Isolation and culture of such cells is well known to those skilled in the art (Rao (Ed.), Stem Cells and CNS Development, Humana Press Inc., New Jersey (2001 ); Fedoroff and Richardson (Eds.), Protocols for Neural Cell Culture, Humana Press Inc., 3rd edition, New Jersey, (2001 )).
The term "insulin-producing cell" means a cell capable of expressing, producing, and secreting insulin.
The term "cultivation medium" means a suitable medium capable of supporting growth and differentiation of stem cells, preferably ES and EG cells. Examples of suitable culture media in practising the present invention are prepared with a base of Dulbecco's modified Eagle's medium (DMEM, Life Technologies) supplemented with 1 5% heat-inactivated foetal calf serum (FCS, Gibco), and additives, such as 2 mM L-glutamine (Gibco), 5 x 1 0"6M ?-mercaptoethanol (Serva) and 1 : 1 00 non-essential amino acids (Gibco) . Another example is a culture medium comprising Iscove's modified
Dulbecco's medium (IMDM, Gibco) supplemented with 20% FCS, 2 mM L- glutamine (Gibco), 1 : 100 non-essential amino acids (Gibco) and 450 μM a- monothioglycerol (Sigma) . For routine cultures, ES cells are grown on a feeder layer of embryonic fibroblasts inactivated by treatment with 100 μg/ml mitomycin C for 3 hours.
The term "differentiation medium" means a suitable medium for inducing the differentiation of stem cells into insulin-producing cells. Examples of suitable culture media in practising the present invention are prepared with a base of Iscove's modified Dulbecco's medium (IMDM, Gibco) supplemented with 20% fetal calf serum (FCS), 2mM L-glutamine, 1 : 1 00 non-essential amino acids and 450 μM σ-monothioglycerol (Sigma) . In addition, such medium can contain between 1 ng/ml and 100 μg/ml, preferably 10 ng/ml Epithelial Growth Factor (EGF); between 1 ng/ml and 100 /g/ml, preferably 2 ng/ml basic Fibroblast Growth Factor (bFGF); between 1 nM and 1 mM, preferably 20 nM progesterone; between 1 0 ng/ml and 100 μg/ml, preferably 100 ng/ml Growth hormone; between 1 nM and 100 μM, preferably 5 nM follistatin (R&D); or between 1 and 100 nM, preferably 2nM activin (R&D). Another example of suitable culture media in practising the present invention is prepared with a base of Dulbecco's modified Eagle's medium: Nutrient Mixture F-1 2 (DMEM/F1 2, Life Technologies) supplemented with between 100 ng/ml and 100 μg/ml, preferably 5 //g/ml insulin; between 1 nM and 100 nM, preferably 30 nM sodium selenite; between 100 ng/ml and 500 μg/ml, preferably 50 μg/ml transferrin; between 100 ng/ml and 100 μg/ml, preferably 5 μg/ml fibronectin. Yet another example of suitable culture media in practising the present invention is prepared with a base of Dulbecco's modified Eagle's medium: Nutrient Mixture F-12 (DMEM/F1 2, Life Technologies) supplemented with between 100 ng/ml and 100 μg/ml, preferably 25 μg/ml insulin; between 1 nM and 100 nM, preferably 30 nM sodium selenite; between 1 00 ng/ml and 500 μg/ml, preferably 50 μg/ml transferrin; between 1 00 ng/ml and 100 μg/ml, preferably 5 μg/ml fibronectin;
between 500 ng/ml and 100 μg/ml, preferably 1 μg laminin; between 10 μM and 500 μM, preferably 100 μM putrescine; between 1 nM and 1 μM preferably 20 nM progesterone; between 100 M and 100 mM, preferably 10 mM nicotinamide.
5
In addition, extracellular matrix (ECM) proteins, such as laminin (between 0.5 and 1 00 μg/ml, preferably 1 μg/ml, SIGMA), or collagens, or complex mixtures of growth factors and ECM proteins of basal lamina (Matrigel R, Collaborative Research/Becton Dickinson, 1 :3 dilution = stock solution, o final concentration in cultures = 1 : 10) are included to enhance the number of pancreatic cells as well as their differentiation status.
The term "terminal differentiation medium" means a suitable medium for terminal differentiation of insulin-producing cells. Examples of suitable 5 culture media in practising the present invention are prepared with a base of Iscove's modified Dulbecco's medium (IMDM, Gibco) supplemented with 20% FCS, 2mM L-glutamine, 1 : 100 non-essential amino acids and 450 μM σ-monothioglycerol (Sigma) . In addition, such medium can contain between 1 nM and 1 00 μM, preferably 2 nM Activin A; between 1 nM and 1 00 μM, o preferably 1 nM betacellulin; between 1 ng/ml and 1 00 μg/ml, preferably 10 ng/ml Human Growth Factor (HGF); between 1 nM and 100 μM, preferably 10 nM Niacinamid and between 1 ng/ml and 100 μg/ml, preferably 2 ng/ml Transforming Growth Factor 2beta (TGF 2beta).
5 The term "pancreatic gene" means a gene or its protein product that is involved and required for pancreas development, more preferably beta-cell differentiation. Examples of such genes are Pdx1 (GenBank accession number AH00571 2), Pax4 (GenBank accession numbers XM004974, NM0061 93), Pax6 (GenBank accession number M93650), ngn3 (GenBank 0 accession numbers XM005744, NM020999, AJ1 33776), Nkx6.1 (GenBank accession number AH007313), Nkx6.2, Nkx2.2 (GenBank accession number AF01 941 5), HB9 (GenBank accession numbers
XM049383, AF1 07457), BETA2/NeuroD (GenBank accession numbers NM002500, XM002573), Isl1 (GenBank accession number NM002202), HNF1 -alpha, HNF1 -beta (GenBank accession number X71 346), and HNF3 (GenBank accession numbers AF1 761 1 2, AF1 761 1 1 ) of human or animal origin. Preferred genes are Pdx1 , Pax4, Pax6, and ngn3. Especially preferred genes are Pdx1 , Pax4, and Pax6. Each gene can be used individually or in combination.
The term "activating one or more pancreatic gene" means delivering and introducing said pancreatic genes or proteins into stem cells.
In a preferred embodiment, the cDNA of one or more pancreatic genes is placed under the control of a regulatory region allowing the initiation of transcription and introduced into a cell by transfection methods such as electroporation, lipofection, calcium phosphate mediated, DEAE dextrans, and the like. Such methods and system are well described in the art and do not require any undue experimentation; see, for example, Joyner, "Gene Targeting: A Practical Approach", Oxford University Press, New York, 1 993; Mansouri "Gene Targeting by Homologous Recombination in Embryonic Stem Cell", Cell Biology: A Laboratory Handbook, second ed.. Academic Press, 1 998. Gene expression of pancreatic gene can be assured by constitutive promoters such as the Cytomegalovirus promoter/enhancer region or inducible promoters such as the tetracycline inducible system. Expression vectors can also contain a selection agent such as the neomycin, hygromycin or puromycin resistance genes. Making such gene expression vectors are well known in the art; see Sambrook et al , "Molecular Cloning, A laboratory Manual" third ed., CSH Press, Cold Spring Harbor, 2000; Gossen and Bujard, (1 992) Proc. Natl. Acad. Sci. USA 89:5547-5551 ) . DNA transfer can also be achieved using a viral delivery system such as retrovirus, adenovirus, adeno-associated virus and lentivirus vectors.
In a further preferred embodiment, protein products of pancreatic genes can be delivered directly to stem cells. For example, protein delivery can be achieved by polycationic liposomes (Sells et al. (1 995) Biotechniques 19:72-76), Tat-mediated protein transduction (Fawell et al. (1 993) Proc. Natl. Acad. Sci. USA 91 :664-668) and by fusing a protein to the cell permeable motif derived from the PreS2-domain of the hepatitis-B virus (Oess and Hildt (2000) Gene Ther. 7:750-758). Preparation, production and purification of such proteins from bacteria, yeast or eukaryotic cells are well known by persons skilled in the art.
An additional embodiment of the present invention relates to a method for aggregating stem cells, preferably ES and EG cells, to form embryoid bodies. Embryoid bodies can be generated by a hanging drop method. For example, between 400-800 ES cells, preferably 600, are cultured in drops of 20 μl of Iscove modified Dulbecco's medium (IMDM, Gibco) supplemented with 20% FCS, L-glutamine, non-essential amino acids and αr-monothioglycerol placed on the lids of petri dishes filled with phosphate- buffered saline (PBS) . Embryoid bodies are cultured in hanging drops for 2 days at 37°C with 5% C02 and then transferred to bacteriological petri dishes (Greiner, Germany) and incubated a further 3 days in suspension culture. After 5 days, embryoid bodies are plated onto gelatin-coated 24- well plates, petri dishes or other suitable culture container and cultured for an additional 1 5 to 35 days at 37°C with 5% C02. Embryoid bodies can also be produced in spinner cultures. For example, adherent stem cells are enzymatically dissociated using 0,2% trypsin and 0,05% EDTA in PBS (Life Technologies) and seeded at a density of 107 cell/ml in 250 ml siliconised spinner flasks (Life Technologies) containing 100 culture medium. After 24 hours, 1 50 ml culture medium is added to a final volume of 250. Spinner flasks are stirred at 20 rpm using a stirrer system (Integra Biosciences) . Such methods are well known in the art and can be scaled up for industrial production without undue experimentation.
In a further embodiment of the invention, embryoid bodies are plated unto petri dishes containing differentiation medium and allowed to differentiate into insulin-producing cells for periods of 1 5 to 50 days, preferably 20 to 25 days (depending on the cell lines used; R1 wild type cells need longer differentiation for generating insulin or glucagon-positive cells than Pdx-1 + or Pax4+ cells) . In the method of the invention a high proportion of insulin- producing cells is obtained. After a differentiation time of 1 5 days, the proportion of insulin-producing cells is preferably at least 20%, more preferably at least 40% and most preferably at least 50%.
The proportion of insulin-producing cells may further be increased by a selection of nestin-positive cells. This selection preferably comprises the transfer of embryoid bodies, e.g. obtained by the hanging drop method, to a suspension culture and subsequent plating and/or replating on a suitable medium, e.g. a poIy-L-ornithine/Iaminin coated plate. The nestin selection procedure may lead to a further increase in the proportion of insulin- producing cells, e.g. a proportion of 70% or more.
In a further embodiment of the invention, differentiated insulin-producing cells can be isolated and purified using a method for selecting insulin secreting cell clones from ES cells by transfecting cells with a plasmid allowing the expression of neomycin, hygromycin or puromycin resistance gene under the control of the regulatory region of the human insulin gene. Cells can also be sorted using Fluorescent Activated Cell Sorting (FACS) after Hoechst 33342 dye staining (Goodell et al. (1 996) J. Exp. Med. 183: 1 797-1 806) . Further modifications of the above-mentioned embodiment of the invention can easily be devised by the person skilled in the art, without undue experimentation from this disclosure.
An additional embodiment of the present invention relates to a method for treating diabetes wherein between 3000 and 1 00 000 equivalent differentiated insulin-producing cells per kilogram body weight would be
introduced into a diabetic patient intraportally via a percutaneous transhepatic approach using local anaesthesia. Such surgical techniques are well known in the art and can be applied without any undue experimentation, see Pyzdrowski et al, "Preserved insulin secretion and insulin independence in recipients of islet autografts" New England J. Medicine 327:220-226, 1 992; Hering et al , "New protocol toward prevention of early human islet allograft failure" Transplantation Proc. 26:570-571 , 1 993; Shapiro et al , "Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen", New England J. Medicine 343:230-238, 2000. Furthermore, encapsulation technology could also be used for the transplantation of differentiated insulin-producing cells as described by Lanza et al , "Encapsulated cell technology", Nature Biotech 14: 1 107- 1 1 1 1 , 1 996.
Further, the invention relates to a cell composition comprising differentiated stem cells exhibiting insulin production, e.g. an insulin- producing cell line obtainable by the method as described above. The insulin-producing cells may exhibit a stable or a transient expression of at least one gene involved in β-cell differentiation, particularly a gene as described above. The cells are preferably human cells which are derived from human stem cells. For therapeutic applications the generation of autologous human cells from adult stem cells of a patient is especially preferred.
The insulin-producing cells of the invention exhibit characteristics which closely resemble naturally occurring β-cells. Particularly, the ratio of insulin- producing cells versus glucagon-producing cells is high. After 1 5 days of differentiation, this ratio is preferably at least 2: 1 and more preferably at least 5: 1 . Further, the cells of the invention are capable of a quick response to glucose. After addition of 27.7 mM glucose, the insulin production is enhanced by a factor of at least 2, preferably by a factor of
at least 3 in the cells of the invention. Further, the cells of the invention are capable of normalizing blood glucose levels after transplantation into mice.
The cell composition of the invention is preferably a pharmaceutical composition comprising the cells together with pharmacologically acceptable carriers, diluents and/or adjuvants. The pharmaceutical composition is preferably used for the treatment of diabetes. The administration is preferably by transplantation as described above.
In a further embodiment, the present invention allows the generation of cells for the identification and/or characterisation of compounds which stimulate beta-cell differentiation, insulin secretion or glucose response. This method is particularly suitable for in vivo testing for diagnostic applications and drug development or screening. The compound of interest is added to differentiated and undifferentiated insulin-producing cells which are grown in appropriate culture system, for example 96 and 384 well plates. Insulin levels in treated cells can be quantified by Enzyme Linked lmmunoabsorbent Assay (ELISA) or Radio Immuno Assay (RIA) . Using this method, a large number of compounds can be screened and compounds that induce beta-cell differentiation and increase insulin secretion can be identified readily.
Preferred embodiments for high-throughput screening and medium throughput validation methods are described in Fig. 1 1 . In a high- throughput screening method, the cells are transfected with a DNA construct, e.g. a viral or non-viral vector containing a reporter gene, e.g. the lacZ gene or the GFP gene, under regulatory control of a promoter of a gene involved in β-cell differentiation, e.g. a promoter of a gene as described above, preferably a Pax4 promoter. The transfected cells are divided into aliquots and each aliquot is contacted with a test substance, e.g. candidate 1 , candidate 2 and candidate 3. The activity of the reporter
gene corresponds to the capability of the test compound to induce β-cell differentiation.
In a further embodiment (which may be combined with the high-throughput screening as described above) a medium throughput validation is carried out. Therein, the test compound is added to stem cells being cultivated and the insulin production is determined. Following an initial high throughput assay, such as the cell based assay outlined above where e.g. a Pax4 promoter is used as marker for beta-cell regeneration, the activity of candidate molecules to induce beta-cell differentiation is tested in a validation assay comprising adding said compounds to the culture media of the embryoid bodies. Differentiation into insulin-producing cells is then evaluated, e.g. by comparison to wild type and/or Pax4 expressing ES cells to assess the effectiveness of a compound.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 : Expression vectors containing the Pdx1 , Pax4, Pax6, and ngn3 gene.
The Pdx1 , Pax4, Paxδ, and ngn3 (SEQ ID No. 1 , 2, 3, 4) cDNA were inserted into the expression vector pACCMV.pLpA previously described by Becker et al. (Becker et al. (1 994) Meth. Cell Biol. 43: 1 61 -1 89). Briefly, a Kpn l-Bam HI fragment that included the Pdx1 cDNA (SEQ ID No.1 ) was introduce into the Kpnl-BamHI sites of pACCMV.pLpA, placing the Pdx1 gene under the control of the Cytomegalovirus (CMVp) promoter. Likewise, a Bam Hl-Hind III fragment that include the Pax4 cDNA (SED ID No. 2) was introduce into the Bam Hl-Hind III sites of pACCMV.pLpA, placing the Pax4 gene under the control of the CMV promoter; a Bam Hl-Hind III fragment that includes the Pax6 cDNA (SED ID No.3) was introduced into the Bam Hl-Hind III sites of pACCMV.pLpA, placing the Pax6 gene under the control of the CMV promoter; and a Bam Hl-Xba I that includes the ngn3 cDNA
(SEQ ID No. 4) was introduced into the Bam Hl-Xba I sites of pACCMV.pLpA, placing the ngn3 gene under the control of the CMV promoter. Abbreviations: B, Bam HI; H, Hind III; K, Kpn I; X, Xba I; Ad 5, adenovirus type 5.
Figure 2. Differentiation of ES cells into insulin-producing cells
Wild type and Pdx1 expressing embryonic stem (ES) cells were cultivated as embryoid bodies (EB; EBs) by the hanging drops method. Differentiation and terminal differentiation media are applied upon plating of EBs.
Figure 3. Amount of hormone-producing cells in Pdx1 + differentiated ES cells
Immunofluorescence observation of insulin, glucagon, pancreatic polypeptide (PP) and somatostatin-positive cells following plating of Pdx1 + embryoid bodies cultured in normal culture medium and differentiation medium. Results illustrated over time in arbitrary units representing the average number of hormone-producing cells in define areas of the culture dishes. The number of hormone-producing cells (i.e. insulin, glucagon, PP, and somatostatin) is higher when embryoid bodies are cultured in differentiation and terminal differentiation media.
Figure 4. Expression of pancreas specific genes after differentiation of wild type, Pdx1 +, and Pax4+ ES cells into insulin-producing cells.
mRNA levels of pancreas specific genes following formation of embryoid bodies by the hanging drop method and plating in differentiation medium. Insulin and Glut2 levels are higher in Pdx1 + and Pax4+ ES cells than in wild type ES cells indicating that differentiation is more efficient when a pancreatic developmental control gene is activated.
Figure 5. Differentiation of mouse ES cells into insulin-producing cells.
The proportion of insulin-producing cells was determined in wild type cells (R1 ), and Pdx1 and Pax4 expressing cells, 5, 6, 10, and 1 5 days after plating.
Figure 6. Insulin-producing cells versus glucagon-producing cells.
The expression of insulin and glucagon in wild type ES cells, Pdx1 expressing cells and Pax4 expressing cells was determined 5, 10 or 1 5 days after plating.
Figure 7. Glucose response of Pax4 ES cell derived insulin cells.
The insulin secretion of wild type (R1 ) and Pax4 ES derived insulin- producing cells was determined in the absence of glucose and 1 5 minutes after stimulation with 27.7 mM glucose.
Figure 8. Regulation of blood glucose level in diabetic mice.
The blood glucose level of diabetic control mice (STZ control) and diabetic mice having received a transplant of insulin-producing cells derived from Pax4 ES cells was determined.
Figure 9. Drug screening strategies.
A high-throughput screening and a medium throughput validation method for three test compounds are shown. An initial high throughput screen is performed in a cell assay using Pax promoters as reporter for beta-cell differentiation. Positive candidates are then validated in a medium throughput assay involving embryoid bodies. Compounds are tested at
different stages of culture for their potential to induce the formation of insulin-producing cells.
Figure 10. Differentiation methods of ES cells into insulin-producing cells using culture conditions favouring the formation of nestin-positive cells.
Figure 1 1. Differentiation of nestin-positive mouse ES cells into insulin- producing cells.
EXAMPLES
A better understanding of the present invention and of its many advantages will be had from the following examples, given by way of illustration.
Example 1 : Generation of ES cells expressing the Pdx1 or Pax6 gene.
The mouse R1 ES cells (Nagy et al. (1 993) Proc. Natl. Acad. Sci. U S A. 90:8424-8) were electroporated with the Pax6 or the Pdx1 gene under the control of the CMV promoter (see figure 1 ) and the neomycin resistance gene under the control of the phosphoglycerate kinase I promoter (pGK-1 ) . ES cells are cultured in Dulbecco's modified Eagle's medium (DMEM, Life Technologies) containing 4.5 g/l glucose, 1 0"4 M beta-Mercaptoethanol, 2nM glutamine, 1 % non essential amino acids, 1 nM Na-pyruvate, 1 5% FCS and 500 U/ml leukaemia inhibitory factor (LIF) . Briefly, approximately 1 07 ES cells resuspended in 0.8 ml phosphate buffered saline (PBS) containing 25 μg/ml of linearized expression vector and electroporated with one pulse of 500 μF and 250 volts at room temperature using a Gene Pulser electroporation apparatus (BioRad) . Five minutes after electroporation, ES cells are plated on 8.5 cm petri dishes containing fibroblastic feeder cells previously inactivated by treatment with 1 00 μg/ml mitomycin C for 3 hours. One day after electroporation, culture medium is
changed to medium containing 450 μg/ml G41 8. Resistant clones are separately isolated and cultured 14 days after applying the selection medium. Cells are always cultured at 37°C, 5% C02.
Example 2: Differentiation of ES cells into insulin-producing cells.
The ES cell line R1 (wild type, wt) and ES cells constitutively expressing Pdx1 (Pdx1 + ) were cultivated as embryoid bodies (EB; EBs) by the hanging drops method (Figure 2) . Briefly, approximately 600 cells were placed in drops of 20 l medium composed of Iscove modified Dulbecco's medium (IMDM, Gibco) supplemented with 20% FCS, L-glutamine, non- essential amino acids and alpha-monothioglycerol (Sigma, Steinheim, Germany; final concentration 450 μM). Drops were placed on the lids of petri dishes filled with phosphate-buffered saline (PBS) . The EBs were allowed to form in hanging drops cultures for 2 days and then transferred for three days to suspension cultures in bacteriological petri dishes (Greiner, Germany) . At day 5, EBs were plated separately onto gelatin- coated 24-well plates containing a differentiation medium prepared with a base of Iscove modified Dulbecco's medium (IMDM, Gibco) supplemented with 20% FCS, 2mM L-glutamine, 1 : 100 non-essential amino acids, 450 μM σ-monothioglycerol (Sigma), 10 ng/ml Epithelial Growth Factor (EGF, R&D Research), 2 ng/ml basic Fibroblast Growth Factor (bFGF, R&D Research), 20 nM progesterone (R&D Research), 100 ng/ml Human Growth Hormone (HGH, R&D Systems) and 5 nM follistatin (R&D Systems) and/or 2nM human activin A (R& D Systems) . Cells were cultured for 1 5 to 40 days in the differentiation medium. To enhance differentiation capacity, a terminal differentiation medium can be applied at stages between 5 and 20 days after EB plating.
Example 3. Hormonal expression in differentiated ES cells.
Expression of insulin, glucagon, somatostatin and pancreatic polypeptide (PP) was verified by immunofluorescence in differentiated wt and Pdx1 + ES cells. Immunofluorescence was performed according to standard protocols (see Wobus et al.: In Vitro Differentiation of Embryonic Stem Cells and Analysis of Cellular Phenotypes, In: Tymms, M.J. and Kola, I. (Eds.) Gene Knockout Protocols, vol. 1 58, Methods in Molecular Biology, Humana Press, Totowa, New Jersey, 2001 ). Briefly, differentiated wt or Pdx1 + ES cells are grown on cover slips and rinsed twice with PBS and fixed with methanol: acetone 7:3 at -20°C for 10 min. The following antibodies were used: Mouse anti-insulin (Sigma-Aldrich Co.), rabbit anti- glucagon (Dako Corporation), rabbit anti-somatostatin (Dako Corporation), rabbit anti-PP (Dako Corporation) were used as primary antibody while Fluorescein (DTAF)-conjugated goat anti-mouse IgG (Jackson ImmunoResearch Laboratories) and Cy3™-conjugated goat anti rabbit IgG (Jackson ImmunoResearch Laboratories) were used as second antibody. In this study double immunostaining was performed, and the following pairs of antibodies were used: anti-insulin and anti-glucagon; anti-insulin and anti-somatostatin; anti-insulin and anti-PP. Cells were analyzed with a fluorescence microscope Optiphot-2 (Nikon) and a confocal laser scanning microscope (CLSM) LSM-410 (Carl Zeiss). Differentiated wt ES cells co- express insulin, glucagon, PP, and somatostatin indicating that the cells have not undergone maturation into single hormone-producing cells. However, differentiated Pdx1 + cells separately express either insulin or glucagon but, rarely both hormones at the same cells demonstrating that such cells achieve maturation into single hormone-producing cells. The number of hormone-producing cell is higher when Pdx1 + ES cells are cultured in a differentiation medium (see Fig.3) illustrating that differentiation into insulin-producing cells is more efficient when a pancreatic developmental control gene is expressed in a stem cell (e.g. ES) and when such cells are cultured in a differentiation medium.
Example 4: Expression of pancreas specific genes after differentiation of ES cells into insulin-producing cells.
Expression levels of pancreas specific genes was measured by semi- quantitative RT-PCR analysis. Differentiated wild type, Pdx-1 + and Pax4+ cells have been collected after embryoid body formation (5d) and 2, 7, 10, 1 5, 21 and 24 days after plating (5 + 2d, + 7d, + 10d, + 1 5d, + 21 d, + 24d) were suspended in lysis buffer (4 M guanidinium thiocyanate, 25 mM sodium citrate, pH 7; 0.5% sarcosyl, 0.1 M beta-mercaptoethanol) . Total RNA was isolated by the single step extraction method described by Chomczynski and Sacchi (Chomczynski and Sacchi (1 987) Anal. Biochem. 162: 1 56-1 59) . mRNA was reverse transcribed using PolyT tail primer Oligo d(T)16 (PerkinElmer) and the resulting cDNA was amplified using oligonucleotide primers complementary and identical to transcripts of the following genes: GLUT2 (SEQ ID No 9 and 1 0; annealing temperature 60°C for 40 cycles, expected fragment size 556 bp), insulin (SEQ ID No 1 1 and 1 2; annealing temperature: 60°C for 40 cycles, expected fragment size 340 bp), ngn-3 (SEQ ID No 13 and 14; annealing temperature: 60°C for 40 cycles, expected fragment size 514 bp), Pdx-1 (SEQ ID No 1 5 and 1 6; annealing temperature: 60°C for 45 cycles, expected fragment size 230 bp) and Isl 1 (SEQ ID No 1 7 and 1 8; annealing temperature: 60°C for 40 cycles, expected fragment size 514 bp). The house keeping gene beta- tubulin (SEQ ID No 1 9 and 20, annealing temperature: 60°C for 28 cycles, expected fragment size 31 7 bp) was used as internal standard. Reverse transcription (RT) was performed with MuLV reverse transcriptase (Perkin Elmer) . Multiplex PCRs were carried out using AmpliTaq DNA polymerase (Perkin Elmer) as described in Wobus at al., 1 997. Briefly, RT reactions (20 μl) were performed with MuLV reverse transcriptase. Separate PCRs using primers of the analysed genes or primers of the house keeping gene beta- tubulin were carried out with 3 μl of the RT products.
mRNA levels of genes encoding Pax4 and insulin were analysed using the Dynalbeads mRNA DIRECT micro kit (Dynal) according to the manufacturer's instructions.
One third of each PCR reaction was separated by electrophorese on 2% agarose gels containing 0.35 μg/ml of ethidium bromide. Gels were illuminated with UV light and the ethidium bromide fluorescence signals of gels were stored by the E.A.S.Y. system (Herolab) and analyzed by the TINA2.08e software (Raytest Isotopenmeβgerate GmbH). The intensity of the ethidium bromide fluorescence signals was determined from the area under the curve for each peak and the data of target genes were plotted as percentage changes in relation to the expression of the housekeeping gene beta-tubulin.
Results show that markers for beta-cell differentiation function were expressed at higher levels in Pdx1 + and Pax4+ differentiated ES cells than in differentiated wild type ES cells demonstrating that activation of a pancreatic developmental control gene renders differentiation more efficient than for wild type ES cells (Figure 4) . Expression of GLUT2 in differentiated stem cells indicates that hormone-producing cells are capable of responding to glucose. In addition, genes involved in early endodermal/pancreatic precursor cell specification such as ngn3 and Isl1 are downregulated in Pdx-1 + and Pax4+ ES cells, consistent with in vivo data indicating that such cells have matured into single hormone-producing cells.
Example 5: Hormonal expression of differentiated ES cells expressing Pdx1 and Pax4
In order to study the potential of pancreatic developmental control to induce beta-cell differentiation in vitro, we have generated stable mouse embryonic stem (ES) cells expressing the Pax4 or Pdx1 gene under the
control of the cytomegalovirus (CMV) early promoter/enhancer region (see Figure 1 a,b). The CMV-Pax4 and CMV-Pdx1 transgenes were introduced into ES cells by electroporation, a method that is well known in the art, for example see Joyner, "Gene Targeting: A Practical Approach", Oxford University Press, New York, 1 993; Mansouri "Gene Targeting by Homologous Recombination in Embryonic Stem Cell", Cell Biology: A Laboratory Handbook, second ed., Academic Press, 1 998. Pax4, Pdx1 and wild type ES cells were then cultured in hanging drops or spinner cultures to allow the formation of embryoid bodies. Embryoid bodies were subsequently plated and cultured in a differentiation medium containing various growth factors. Under such conditions, insulin-producing cells can be detected in Pdx1 and Pax4 expressing cells six days after plating (Figure 5) . By comparison, wild type ES cells did not contain any insulin-producing cell at the same stage. Ten days after plating, 1 2% of Pdx1 and Pax4 expressing cells were positive for insulin while the first insulin-producing cells are observed in wild type ES cells. At day 1 5 of plating, up to 60% of the Pax4 ES cells are positive for insulin compared to 22% for Pdx1 ES cells and 6% for wild type ES cells. These data demonstrate that Pax4, and to some extent Pdx1 , can significantly promote, and enhance ES cells differentiation into insulin-producing cells compared to wild type ES cells.
The expression of Pax4 also affects the differentiation status of the insulin- producing cell. During embryogenesis, the first hormone-producing cells to arise in the developing pancreas co-express both insulin and glucagon. These cells subsequently differentiate and mature into single hormone- producing cells. In a similar fashion, all insulin-producing cells obtained from wild type ES cells also co-express glucagon suggesting that differentiation of the cells is arrested at a premature stage (Figure 6) . Such cells most likely have little therapeutic value since insulin and glucagon have opposing effect on blood glucose levels in an organism. However in Pax4 ES cells, single insulin-producing cells are generated in substantial amounts (Figure 6) . Insulin-glucagon co-expressing cells are detected in
small numbers and most likely represent an ongoing differentiation process within the cultures. This observation demonstrate that Pax4 induces, and enhances the differentiation of insulin-producing cells which are more mature than the cells observed in wild type ES cells.
Example 6: Functional characterisation of the differentiated insulin- producing cells.
One important property of beta-cells is glucose responsive insulin secretion. To test whether the Pax4 derived insulin-producing cells possessed this glucose responsive property, in vitro glucose responsive assay was performed on the differentiated cells. Briefly, between 10 and 14 embryoid bodies were cultured in 3 cm petri dishes containing the above mentioned differentiation medium. On the day of the assay, the differentiation medium was removed and the cells were washed 3 times with Krebs Ringer Bicarbonate Hepes Buffer (KRBH; 1 1 8 mM NaCl, 4.7 KCI, 2.5 mM CaCI2, 1 ,2 mM KH2P04, 1 .2 mM MgS04, 24.6 NaHCO3, 10 mM Hepes, 2 mg/ml BSA) . Cells were then incubated in 750 μl KRBH for 45 minutes at 37°C. The KRBH was then kept for measurement of basal insulin secretion and 750 μl KRBH containing 27.7 mM glucose was added to the cells. After 1 5 minutes incubation at 37°C, the KRBH was removed from the cells for measurement of glucose induce insulin secretion. Insulin levels were determined by Enzyme-Linked Immunosorbent Assay (ELISA) for mouse insulin (Mercodia) and performed according to the manufacturer's recommendations. An alternative medium for proper insulin release is medium based on DMEM with glucose concentration of 1 g/I (Gibco) supplemented with non-essential amino acids (Gibco, stock solution 1 : 1 00) and additional factors mentioned above. Such medium can be applied 1 to 6 days before use of the cells.
A basal insulin secretion is observed when both wild type and Pax4 ES derived insulin-producing cells are cultured in the absence of glucose
(Figure 7) . However, only the Pax4 ES derived insulin-producing cells respond to glucose stimulation. In the presence of glucose, a five fold increase in insulin secretion is seen in Pax4 ES derived insulin-producing cells. Wild type ES derived insulin-producing cells do not respond to glucose.
Example 7: Transplantation of Pax4 ES derived insulin-producing cells in STZ diabetic mice.
The therapeutic potential of Pax4 ES derived insulin-producing cells to improve and cure diabetes was investigated by transplanting the cells into streptozotocin induced diabetic mice. Streptozotocin is an antibiotic which is cytotoxic to beta-cells when administered at certain dosage (see Rodrigues et al.: Streptozotocin-induced diabetes, in McNeill (ed) Experimental Models of Diabetes, CRC Press LLC, 1 999) . Its effect is rapid, rendering an animal severely diabetic within 48 hours.
Non-fasted Male BalbC mice were treated with 1 70 mg/Kg body weight STZ. Under such conditions, 1 7 control mice developed hyperglycaemia 6 days after STZ treatment. Mice are considered diabetic if they have a blood glucose level above 10 mMol/l for more than 3 consecutive days. One mouse did not respond to the STZ treatment. Elevated blood glucose levels varied significantly between animals and between days. This is indicative of diabetes since the animals cannot regulate their blood glucose. Cells were transplanted under the kidney capsule and into the spleen of animals. Briefly, mice were anaesthetised by intraperitoneal injection of 1 5 μl/g body weight avertin (2,5% tribromoethyl alcoho tertiary amyl alcohol) . The kidney and the spleen was exposed through a lumbar incision, and cells were transferred into each tissue using a blunt 30G needle.
Transplantation of cells under the kidney capsule and into the spleen were performed 24-48 hours after STZ treatment. 8 animals were transplanted
with between 1 x 106 and 5 x 106 Pax4 ES derived insulin-producing cells. 4 out of 8 transplanted animals died due to the surgical procedure. Of the 4 animals that did survived, none developed diabetes when compared with STZ-treated control animals (Figure 8). The presence of the insulin- producing cells was confirmed by immunohistological analysis of the transplanted tissue. These results demonstrate that the transplanted cells can normalise blood glucose in diabetic animals.
Example 8: Differentiation of ES cells into insulin-producing cells using culture conditions favouring the formation of nestin-postive cells.
For differentiation of nestin-positive cells, mouse ES cells were cultivated for 2 days in hanging drops (100, 200, or 400 cells/drop) to form embryoid bodies (EBs; Figure 10) . EBs were then transferred to bacteriological petri dishes (Greiner, Germany) and cultivated for additional 2 days in Iscove's modification of DMEM (IMDM; Gibco) containing 20% FCS and supplements as described (Rohwedel et al., 1 998), Dev. Biol. 201 (2) : 1 67- 184), with the exception that beta-mercaptoethanol was replaced by 450 mM alpha-monothioglycerol (Sigma, Steinheim, Germany) . Between 20 and 30 EBs were plated onto tissue culture dishes (diameter 6 cm) at day 4, and cultivated in IMDM supplemented with 20% FCS for 24 hours. The selection of nestin-positive cells was carried out according to the method described by Okabe and colleagues (Okabe et al., 1996, Mech. Dev. 59:89-102) with the following modifications: After attachment of EBs (day 4 + 1 ), the medium was exchanged for a B1 medium prepared with a base of Dulbecco's modified Eagle's medium: Nutrient Mixture F-1 2 (DMEM/F1 2, Life Technologies) supplemented with 5 mg/ml insulin, 30 nM sodium selenite (both from Sigma), 50 mg/ml transferrin, and 5 mg/ml fibronectin (both from Gibco). The B1 culture medium was replenished every 48 hours. Nestin-positive cells were selected after cultivation for 7 days ( = 4 + 7d). At day 4 + 8, EBs were dissociated with 0.1 % trypsin (Gibco)/0.08% EDTA (Sigma) in phosphate buffered saline (PBS) ( 1 : 1 ) for
1 min, collected by centrifugation, and replated onto poly-L- ornithine/laminin-coated tissue culture dishes containing a B2 medium prepared with a base DMEM/F12 supplemented with 10% FCS; 20 nM progesterone; 1 00 mM putrescine; 1 mg/ml laminin (all from Sigma); 25 mg/ml insulin; 50 mg/ml transferrin; 30 nM sodium selenite; B27 supplement; and 10 mM nicotinamide. This medium was replaced after 24 hours with B2 medium lacking FCS. At day 30 of plating; > 75% of the Pax4 ES cells are positive for insulin compared to 20% for wild type ES cells (Figure 1 1 ) .
All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.
Claims (32)
1 . A method for differentiating stem cells into insulin-producing cells comprising: culturing stem cells in a suitable medium and activating at least one gene involved in beta-cell differentiation.
2. The method of claim 1 further comprising: aggregating said cultivated stem cells to form embryoid bodies, cultivating said embryoid bodies in a differentiation medium enhancing β-cell differentiation, identifying, and optionally selecting insulin-producing cells.
3. The method of claim 1 or 2, wherein said stem cells are selected from embryonic stem cells, adult stem cells, somatic stem cells and primordial germ cells.
4. The method of any one of claims 1 -3, wherein said stem cells are of human origin.
5. The method of any one of claims 1 -4, wherein the genes involved in β-cell differentiation are selected from the group consisting of Pdx1 , Pax4, Pax6, ngn3, Nkx6.1 , Nkx6.2, Nkx2.2, HB9, BETA2, NeuroD, IsM , HNF1 -alpha, HNF1 -beta, HNF3, and combinations thereof.
6. The method of claim 5, wherein the genes are selected from Pdx1 , Pax4, Pax6, ngn3, and combinations thereof.
7. The method of claim 5 or 6, wherein the genes are of human origin.
8. The method of any one of claims 1 -7, wherein the gene activation comprises a delivery of a pancreatic gene into stem cells.
9. The method of claim 8, wherein said gene delivery comprises a transfection of stem cells with a cDNA of at least one pancreatic gene under the control of a regulatory region allowing the initiation of transcription.
1 0. The method of claim 8, wherein said gene delivery comprises a DNA transfer using a viral delivery system.
1 1 . The method of any one of claims 1 -7, wherein the gene activation comprises a delivery of a protein product of a pancreatic gene into stem cells.
1 2. The method of any one of claims 2-1 1 , wherein said embryoid bodies are formed by a hanging drop method.
1 3. The method of any one of claims 2-1 2, wherein said differentiation medium is based on Iscove's modified Dulbecco's medium (IMDM) supplemented with fetal calf serum, L-glutamine, non-essential amino acids, and σ-monothioglycerol optionally containing EGF, bFGF, progesterone, growth hormone, follistatin, and/or activin.
14. The method of claim 1 3, wherein said differentiation medium further contains extracellular matrix proteins, collagens, and/or mixtures of growth factors and extracellular matrix proteins.
1 5. The method of any one of claims 1 -14, wherein at least 20% insulin-producing cells are obtained after a differentiation time of 1 5 days.
1 6. The method of claim 1 5, wherein at least 40% insulin-producing cells are obtained.
1 7. The method of any one of claims 1 -1 6 further comprising a selection of nestin-positive cells.
1 8. The method of any one of claims 1 -17, wherein the insulin- producing cells are used for pharmaceutical applications.
1 9. The method of claim 1 8 for the treatment of pancreatic diseases, metabolic syndrome and metabolic disorders with impaired glucose levels, such as diabetes, hyperglycaemia, and/or impaired glucose tolerance.
20. The method of claim 1 8 or 1 9, wherein between 3000 and 100000 equivalent differentiated insulin-producing cells are administered per kilogram body weight.
21 . A cell composition comprising insulin-producing cells obtainable by the method of any one of claims 1 -1 7.
22. The composition of claim 21 comprising at least 20% insulin- producing cells after a differentiation time of 1 5 days.
23. The composition of claim 22 comprising at least 40% insulin- producing cells.
24. The composition of any one of claims 21 -23 comprising a ratio of insulin-producing cells versus glucagon-producing cells of at least 2: 1 .
25. The composition of claim 24 comprising a ratio of at least 5: 1 .
26. The composition of any one of claims 21 -25 exhibiting an increase in the insulin secretion of at least 2-fold 1 5 min after stimulation with 27.7 mM glucose.
27. The composition of any one of claims 21 -26, which is a pharmaceutical composition.
28. The composition of claim 27 for the treatment of pancreatic diseases, metabolic syndrome and metabolic disorders with impaired glucose levels, such as diabetes, hyperglycaemia, and/or impaired glucose tolerance.
29. The composition of claim 27 or 28, which is administered by transplantation or used in a medical device.
30. A method for identifying and/or characterizing compounds capable of modulating the differentiation of stems cells into insulin-producing cells comprising: contacting a compound to be tested with stem cells under conditions wherein the stem cells are capable of being differentiated into insulin-producing cells and determining the effect of the compound on the differentiation process.
31 . The method of claim 30 comprising transfecting stem cells with a DNA construct containing a reporter gene under regulatory control of a gene involved in β-cell differentiation, contacting said transfected cells with a compound to be tested and determining the activity of the reporter gene.
32. The method of claim 30 or 31 comprising contacting embryoid bodies which are cultivated in a differentiation medium enhancing β- cell differentiation with a compound to be tested and determining differentiation into insulin-producing cells.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60/284,531 | 2001-04-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2002302549A1 true AU2002302549A1 (en) | 2002-11-05 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20050054102A1 (en) | Method for differentiating stem cells into insulin-producing cells | |
JP6893527B2 (en) | SC-β cells and compositions and methods for producing them | |
US8415153B2 (en) | Differentiation and enrichment of islet-like cells from human pluripotent stem cells | |
US9624472B2 (en) | Production of insulin producing cells | |
JP6145117B2 (en) | Differentiation of human embryonic stem cells | |
AU2003302702B2 (en) | Cultured human pancreatic islets, and uses thereof | |
Soria et al. | From stem cells to beta cells: new strategies in cell therapy of diabetes mellitus | |
Mao et al. | The reversal of hyperglycaemia in diabetic mice using PLGA scaffolds seeded with islet-like cells derived from human embryonic stem cells | |
CA2435826A1 (en) | Differentiation of stem cells to pancreatic endocrine cells | |
US20050032207A1 (en) | Method for isolating, culturing and differentiating intestinal stem cells for therapeutic use | |
EP1393066A2 (en) | Insulin producing cells derived from human embryonic stem cells | |
US20130034526A1 (en) | Populations of pancreatic progenitor cells and methods of isolating and using same | |
US20050064587A1 (en) | Pancreatic small cells and uses thereof | |
Kaczorowski et al. | Glucose‐responsive insulin‐producing cells from stem cells | |
Chelluri et al. | Improved differentiation protocol of rat bone marrow precursors to functional islet like cells | |
AU2002302549A1 (en) | A method for differentiating stem cells into insulin-producing cells | |
Bharadwaj et al. | Stem cell’s potential role in the treatment of diabetes mellitus | |
WO2004010933A2 (en) | Insulin-producing cell compositions and related methods | |
Chelluri et al. | Transplant Immunology & Stem Cell Lab., Global Hospitals, Hyderabad; 2 Zoology Department, Osmania University; 3 Centre for Cellular & Molecular Biology, Hyderabad, India Correspondence: Dr. Lakshmi Kiran Chelluri, Head, Transplant Biology & Stem Cell Lab, Global Hospitals, Lakdi-ka-Pool, Hyderabad, 500 004 (AP), India. Tel.+ 91.40. 30244501-Fax:+ 91.40. 23244455 E-mail: lkiran@ globalhospital. net; apparusu@ hotmail. com | |
Palma | Lineage reprogramming of cord blood stem cells | |
AU2002328704A1 (en) | Pancreatic small cells and uses thereof | |
AU2002302945A1 (en) | Insulin producing cells derived from human embryonic stem cells |